Operative ubiquitin-specific protease 22 deubiquitination confers a more invasive phenotype to cholangiocarcinoma

Yu Tian1,2,3, Bo Tang4,6, Chengye Wang1,3, Yan Wang3, Jiakai Mao1, Yifan Yao1, Zhenming Gao1, Rui Liang1, Mingliang Ye3, Shijie Cai5,6 and Liming Wang1,6

© The Author(s) 2021

Oncogenic ubiquitin-specific protease 22 (USP22) is implicated in a variety of tumours; however, evidence of its role and underlying molecular mechanisms in cholangiocarcinoma (CCA) development remains unknown. We collected paired tumour and adjacent non-tumour tissues from 57 intrahepatic CCA (iCCA) patients and evaluated levels of the USP22 gene and protein by qPCR and immunohistochemistry. Both the mRNA and protein were significantly upregulated, correlated with the malignant invasion and worse OS of iCCA. In cell cultures, USP22 overexpression increased CCA cell proliferation and mobility, and induced epithelial-to-mesenchymal transition (EMT). Upon an interaction, USP22 deubiquitinated and stabilized sirtuin-1 (SIRT1), in conjunction with Akt/ERK activation. In implantation xenografts, USP22 overexpression stimulated tumour growth and metastasis to the lungs of mice. Conversely, the knockdown by USP22 shRNA attenuated the tumour growth and invasiveness in vitro and in vivo. Furthermore, SIRT1 overexpression reversed the USP22 functional deficiency, while the knockdown acetylated TGF-β-activated kinase 1 (TAK1) and Akt. Our present study defines USP22 as a poor prognostic predictor in iCCA that cooperates with SIRT1 and facilitates tumour development.

Cell Death and Disease (2021) 12:678 ; https://doi.org/10.1038/s41419-021-03940-0

INTRODUCTION

Cholangiocarcinoma (CCA) is a rare highly malignant bile duct tumour that is classified into intrahepatic CCA (iCCA) and extrahepatic CCA (eCCA) subtypes. The overall incidence of CAA includes 15% of primary liver cancers, the second most common type of primary liver cancer [1, 2]. The incidence of iCCA has increased worldwide over the last few decades [3], there is an unmet need to identify molecular mechanisms that drive this malignancy.

Ubiquitination is one of the main posttranslational modification mechanisms by which regulating protein activation/inactivation, DNA repair, gene regulation and signal transduction [4]. Conjugating ubiquitin to specific proteins through monoubiquitylation or polyubiquitylation is one of the most common posttranslational modifications for regulating protein expression [5, 6]. This process is initiated by ubiquitin-activating enzymes (E1s), followed by ubiquitin-conjugating enzymes (E2s) and ubiquitin ligases (E3s), to modify the targeted proteins [7].

Opposing these enzyme activities, deubiquitination by deubiquitinase (DUBs) removes ubiquitin from the ubiquitinated proteins to maintain physiological homeostasis [8]. So far more than one hundred DUBs have been identified in humans; among them, ubiquitin-specific peptidases (USP) are the largest family [5]. USP22 is one of the subtypes. Under normal physiological conditions, USP22 controls cell cycle progression, protein degradation and embryonic stem cell differentiation [9–12]. By contrast, USP22-associated ubiquitination dysregulation has been implicated in many diseases including tumours [9, 13–18].

USP22 deubiquitylase is a subunit of the transcriptional regulatory histone acetylation complex Spt-Ada-Gcn5 acetyltransferase (SAGA), deubiquitylating the core histone H2B through monoubiquitination by catalysing the removal of ubiquitin from oncoproteins [10, 19]. The induction by USP22 promotes tumour invasion and epithelial-to-mesenchymal transition (EMT), leading to downregulation of E-cadherin and upregulation of N-cadherin, vimentin and matrix metalloproteinases (MMP) [14]. The alterations of these molecules often prevail in malignant lesions. Despite the key role USP22 plays in many types of tumours, evidence for its involvement in CCA development is completely absent and its dichotomous association with different types of tumours—high USP22 expression stimulates breast tumour growth [20], whereas impedes colorectal cancer development [21].

One known substrate of USP22 is sirtuin-1 (SIRT1), a member of the highly conservative mammalian sirtuins family [22–24]. SIRT1 is a highly conserved mammalian NAD+-dependent histone deacetylase, acting as a key metabolic sensor that modulates EMT in tumours [25, 26]. By association with USP22 in the SAGA
complex, SIRT1 targets protein deacetylation on the structures of their histones or non-histones to facilitate tumour progression [11, 15, 27, 28]. However, whether SIRT1 is pro- or anti-tumour growth, particularly its involvement in CCA associated with USP22, remains unknown.

The purposes of this study were therefore to determine the clinical significance of USP22 expression in iCCA, to evaluate the role of USP22 in controlling tumour growth in vitro and in vivo, and to study the underlying molecular mechanisms by which USP22 operates linking SIRT1 for the epigenetic deubiquitination and deacetylation to CCA progression.

MATERIALS AND METHODS

Patients

The iCCA and adjacent non-tumour tissues (2 cm away from the tumours) were collected from patients (n = 57) who underwent surgical treatment from October 2009 to October 2015 at the Department of Hepatobiliary and Pancreatic Surgery of the Second Hospital of Dalian Medical University. Tumour staging was classified according to the International Union Against Cancer to the tumour-node-metastasis (TNM) [29]. The median of follow-up period was 16.7 months. The use of the tissues was approved by our Hospital Ethics Board (No. 2016007). Written informed consent was obtained from patients before the surgery.

Reagents

The Cell Counting Kit-8 (CCK-8), Annexin V-FITC Apoptosis Detection Kit and Cell Cycle Detection Kit were purchased from KeyGen Biotech (Nanjing, China). MG132 and cycloheximide (CHX) were from Sigma (St. Louis, USA).

Cell culture and transfection

Human CCA cell lines RBE and HCCC-9810 (HCCC) were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China), Huh28, HuCCT1, QBC939 were provided by 3D Medicines (Shanghai, China). All cell lines were authenticated by the short tandem repeat (STR). Cells were cultured in RPMI-1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA), 100 µg/ml penicillin and 100 µg/ml streptomycin (Invitrogen, USA) in a 5% CO2 atmosphere at 37°C. All the cell lines were authenticated by STR profiling. siRNAs were used for USP22 transiently silencing. They were transfected with Lipofectamine 2000 reagent (Invitrogen, USA) according to the manufacturer’s instructions. Lentivirus-mediated shRNAs knockdown or gene overexpression of USP22 or SIRT1 were used to construct stable cell lines.

Cell proliferation and colony formation

To measure cell proliferation, 3 × 10^5 cells/well were grown in 96-well plates and CCK-8 kit was used to quantify them. For colony formation assay, 1 × 10^3 cells/well were seeded in six-well plates. After 14 days, colonies were fixed with 4% PFA and stained with 1% crystal violet, in which visible colonies were counted (>50 cells/colony).

Migration and invasion

In terms of migration assay, 2 × 10^5 cells in 200 µl of serum-free medium were plated in an 8 µm pore size transwell inserts and grown in 300 µl of DMEM with 10% fetal bovine serum. For invasion assay, the same culture conditions were applied for the experiment but the insert was precoated with 50 µl of 1 mg/ml Matrigel (BD, Franklin Lakes, NJ, USA). After 24 h, cells migrated to the lower surface of the membrane, after which they were fixed with formalin and stained with 1% crystal violet. Five random fields were selected for the quantification at ×10 magnification.

Western blot

Samples were lysed in RIPA buffer and the lysate protein was determined by BCA assay kit. The protein lysates were separated by 10% SDS-PAGE and transferred onto PVDF membranes. After blocking, their blots were incubated with primary and secondary antibodies, and the bands were visualized by chemiluminescence.

Co-Immunoprecipitation (Co-IP)

Co-IP was done using the PierceTM co-immunoprecipitation kit following the manufacturer’s protocol. Briefly, cell lysates were prepared and the primary antibody was first immobilized for 2 h using Amino Link Plus coupling resin. The resin was then washed and incubated with cell lysates overnight. After protein elution, samples were analysed by immunoblotting.

Immunohistochemistry (IHC)

Tissues were fixed, embedded in paraffin wax and sectioned and prepared for haematoxylin and eosin (H&E) or IHC staining [30]. The intensity of the staining was determined and scored as described previously [31]. These scores were determined independently by two experienced pathologists in a blinded manner.

Immunofluorescence staining

Cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and blocked with 5% bovine serum albumin (BSA). Followed by the primary and secondary antibodies sequentially and DAPI nuclei staining, cells were imaged under laser-scanning confocal microscopy (Zeiss ISM510 META).

Flow cytometry analysis (FACS)

For apoptosis analysis, 1 × 10^6 cells were examined using an Annexin V-FITC Apoptosis Detection kit according to the manufacturer’s instructions. For analysis of E-caderin or Vimentin, 1 × 10^5 cells were seeded in six-well plates. After 48 h, they were detached with an enzyme-free cell dissociation buffer, subsequently fixed with fixation permeabilization solution before proceeding the step with BD perm/wash buffer. Samples were incubated with their respective primary and secondary antibodies and analysed by FACS Calibur (BD Biosciences) analyzer.

Xenograft and metastasis in vivo

Five-week old BALB/c nude male mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. China. They were healthy and their body weight was 25 ± 15 g. Under specific pathogen-free conditions, they were housed in plastic cages, with wood chips, which were changed every week, and each cage was kept to five heads without mixing gender. The dark/light cycle is 12/12 h, and room temperature is kept at 20 ± 2 °C. All the mice were allowed free access to water and sterilised normal chow. All the mice were randomized. The experimental protocols were made in accordance with The Regulations for Animal Experiments in Dalian Medical University, which states replacement, rearing or reduction. The animal experiments were performed in accordance with the Animal Ethics Committee of Dalian Medical University. All the animal experiments were performed and repeated in the Animal Experimental Centre of Dalian Medical University.

TCGA data analysis

The CHOL RNA-seq (HTSeq–Counts) were retrieved from https://portal.gdc.cancer.gov. Differential expression was analysed on the count matrix with DESeq2 package in R software. An adjusted p-value (Padj) < 0.05 was considered significantly statistical. The normalized counts by the sequen- ing depth and adding a pseudocount of 1/2 were extracted with the DESeq2 software package, using the function plotCounts with the argument returnData set to TRUE. Log2(normalized count + 1) was used for log-scale visualization of USP22 expression in tumours and adjacent non-tumour tissues.
Statistical analysis

All experiments were conducted three times. The data of different experimental groups meet normal distribution and the variance is similar between the groups. Values were presented as the mean ± standard deviation (SD). Student’s t-test (two-sided), one-way ANOVA and chi-square ($\chi^2$) analysis were performed to calculate variance. Survival analysis was conducted using the Kaplan–Meier and the log-rank test was used to compare survival rates between groups. $p < 0.05$ indicated statistical significance.

RESULTS

Upregulation of USP22 in patients with CCA

We collected 57 paired iCCA and adjacent normal tissues and analysed their USP22 mRNA expression by qPCR, and showed that USP22 was elevated across all tumour tissues (Fig. 1A), particularly those with invasive lesions ($p < 0.05$) (Fig. 1B). By comparing 36 non-paired CCA (30 iCCA and 6 eCCA) with the non-tumour tissues (https://portal.gdc.cancer.gov/), we showed that the USP22 mRNA was significantly upregulated in CCA ($p < 0.05$) (Supplementary Fig. 1A and 1B), but had no significant correlation with copy numbers of USP22 with either shallow deletion, DNA diploid, or amplification (Supplementary Fig. 1C), hinting the non-genetic regulatory role of USP22 in CCA.

We showed that USP22 protein expression by IHC was consistently upregulated in CCA, present predominantly in the tumour cell nucleus but rarely in any other subtypes of cells (Fig. 1C). The expression was significantly upregulated in tumours ($p < 0.05$) (Fig. 1D). Our correlation analysis based on high IHC scores showed that USP22 was significantly upregulated in CCA ($p < 0.05$) (Fig. 1D), mainly in patients with a larger tumour, microvascular invasion and lymph node metastasis during a complete 57-month follow-up with the median period of 16.7 months (Table 1). Importantly, those patients with high levels of UPS22 protein expression had a worse overall survival (OS) ($p < 0.05$) (Fig. 1E), revealing that USP22 may be a poor prognostic marker to predict CCA progression.

USP22 overexpression stimulates cell proliferation, migration/invasion, and induces EMT in CCA in vitro

Our immunoblotting analysis showed that USP22 was expressed relatively higher in CCA cell lines of RBE, QBC939 and HuhCCT1 than in HCCC and Huh28 (Supplementary Fig. 2A). By transiently transfecting 3 different pairs of siRNAs into RBE confirmed that the second pair gave rise to the better knockdown of the USP22 gene than the other 2 pairs (Supplementary Fig. 2B). Accordingly, we established RBE and QBC939 lines with USP22 stably knockdown by shRNA and designated them as RBE-shSP22 and QBC939-shUSP22, and their controls as RBE-shControl and QBC939-shControl (Supplementary Fig. 2C). By the lentiviral gene transfers of USP22 or empty vector (EV), we established lines of HCCC-USP22 and Huh28-USP22, and the respective HCCC-EV and Huh28-EV controls (Supplementary Fig. 2D).
USP22 overexpression increased cell proliferation (p < 0.05) (Fig. 2A) and colony formation in HCCC-USP22 or Huh28-USP22 compared with HCCC-EV or Huh28-EV controls, respectively (p < 0.05) (Fig. 2C). USP22 silencing decreased cell proliferation and clonogenesis by 3-folds in both RBE-shSP22 and QBC939-shUSP22 compared with RBE-shControl or QBC939-shControl (p < 0.05) (Figs. 2B and D). Furthermore, USP22 overexpression enhanced HCCC and Huh28 cell migration and invasion by ~2–4 folds (p < 0.05) (Fig. 2E and F), while USP22 silencing reduced RBE and QBC939 cell mobility by more than 70% (p < 0.05) (Fig. 2G and H).

Immunofluorescence staining revealed that USP22 overexpression downregulated the cellular membrane localised E-cadherin and upregulated vimentin in HCCC and Huh28 when they were compared with HCCC-EV or Huh28-EV controls (Fig. 2I). Similar results were reproduced by immunoblotting analysis (Fig. 2J) and the quantitative assay of FACS (Supplementary Fig. 3A–3F) (p < 0.05). USP22 enhanced both MMP2/9 expression, the tumour invasive markers (Fig. 2J). The opposite was true when the USP22 gene was knocked down in RBE or QBC939 when collated with the respective controls (Figs. 2K and L, Supplementary Fig. 3G–3L).

**USP22 overexpression induces tumour growth and the metastasis to the lungs of mice in vivo**

We subcutaneously injected cell lines of USP22-overexpressing HCCC-USP22 or USP22-silenced RBE-shUSP22, and their control counterparts into the nude mice. The sizes and weights of HCCC-USP22 tumours were twofolds greater than the HCCC-EV controls (p < 0.05) (Fig. 3A–C). However, RBE-shSP22 tumour sizes and weights were only half of the RBE-shControl (Fig. 3D–F). After a 6-week period of the injection of HCCC-USP22 or HCCC-EV control into the tail veins of the mice, we harvested the lungs and stained the tissue sections with H&E and showed number of the metastatic foci in HCCC-USP22 were twice more than in HCCC-EV (p < 0.05) (Fig. 3G). Conversely, the total number of RBE-shUSP22 metastatic foci were only 1/3 of RBE-shControl (p < 0.05) (Fig. 3H).

**Association of USP22 expression with SIRT1 in CCA**

By immunoblotting analysis, we showed that USP22 overexpression upregulated SIRT1, with increased ERK1/2 and Akt phosphorylation in HCCC-USP22 compared their basal levels with HCCC-EV (Fig. 4A). In contrast, USP22-silenced RBE gave rise to an opposite result (Fig. 4A), suggesting the regulation of SIRT1 and ERK/Akt phosphorylation by USP22. Essentially, USP22 silencing decreased a fraction of SIRT1 expression in RBE and QBC939 (Fig. 4B). Treatment of them with MG132, a proteasome inhibitor, retained the levels of SIRT1 in RBE-shUSP22 or QBC939-shUSP22, which were comparable to the respective RBE-shControl or QBC939-shControl (Fig. 4B). Repeatedly incubating USP22-silenced RBE and QBC939 or the respective controls with cycloheximide (CHX) to block protein translation, we showed downregulation of SIRT1 in a trend of time-independent fashion. At the same time, the level of SIRT1 expression remained constant in RBE-shControl or QBC939-shControl (Fig. 4C), suggesting dependency of SIRT1 expression on USP22 in CCA.

To determine the physical interactions in CCA, we performed Co-IP by immunoprecipitating the endogenous SIRT1 or USP22 proteins and showed the reciprocal immunoprecipitation of them by the respective antibodies from RBE-shUSP22 or RBE-shControl cell lysates, but not by the IgG control (Fig. 4D). Furthermore, we evaluated their interactions by transiently transfecting Flag-tagged SIRT1 or Myc-tagged USP22 alone or co-transfecting them into 293T cells. After 48 h, their cell lysates were prepared for Co-IP and demonstrated the reciprocal immunoprecipitation by the respective antibodies to Flag or Myc (Fig. 4E), reinforcing the presence of the complex formation of SIRT1 and USP22.

To investigate if SIRT1 degradation was ubiquitination-dependent when USP22 was silenced, we repeated the pull-down to detect the endogenous SIRT1 in RBE cell lysates with an antibody to SIRT1 and the IgG isotype control. After immunoblotting with antibodies to ubiquitin, SIRT1, USP22 and GAPDH, we showed that SIRT1 was ubiquitinated and accumulated in the USP22-silenced RBE but not in the control (SIRT1 as the loading control) (Fig. 4F). These findings demonstrate the ubiquitination-mediated SIRT1 degradation when USP22 is downregulated in RBE.

Next, we evaluated the effect of SIRT1 on oncoprotein TGF-β-activated kinase 1 (TAK1) and Akt acetylation and also conducted immunoprecipitation with antibodies to TAK1 and Akt, followed by immunoblotting with antibodies to pan-acetylation, TAK1, Akt, SIRT1 and GAPDH. We showed increased

---

**Table 1.** Immunohistochemical analysis of USP22 expression with clinicopathology of CCA.

| Tumour characteristics | USP22 protein expression | Total | p   |
|------------------------|--------------------------|-------|-----|
|                        | Low | High |          |
| Age (year)             |     |      |          |
| ≤50                    | 7 (47%) | 8 (53%) | 15 | 0.389 |
| >50                    | 25 (60%) | 17 (40%) | 42 |       |
| Sex                    |     |      |          |
| Male                   | 27 (55%) | 22 (45%) | 49 | 0.696 |
| Female                 | 5 (63%) | 3 (37%) | 3  |       |
| γ-GT (U/L)             |     |      |          |
| ≤54                    | 19 (56%) | 15 (44%) | 34 | 0.962 |
| >54                    | 13 (57%) | 10 (43%) | 23 |       |
| Liver cirrhosis        |     |      |          |
| No                     | 2 (67%) | 1 (33%) | 3  | 0.706 |
| Yes                    | 30 (56%) | 24 (44%) | 54 |       |
| Tumor diameter         |     |      |          |
| ≤5                     | 26 (67%) | 13 (33%) | 39 | 0.018 |
| >5                     | 6 (33%) | 12 (67%) | 18 |       |
| Microvascular invasion |     |      |          |
| Absent                 | 22 (73%) | 8 (27%) | 30 | 0.006 |
| Present                | 10 (37%) | 17 (63%) | 27 |       |
| Tumor encapsulation    |     |      |          |
| Complete               | 14 (67%) | 7 (37%) | 21 | 0.221 |
| None                   | 18 (50%) | 18 (50%) | 36 |       |
| Tumor differentiation  |     |      |          |
| I + II                 | 26 (68%) | 12 (32%) | 38 | 0.080 |
| III + IV               | 6 (32%) | 13 (68%) | 19 |       |
| Lymph node metastasis  |     |      |          |
| No                     | 20 (77%) | 6 (23%) | 26 | 0.004 |
| Yes                    | 12 (39%) | 19 (61%) | 31 |       |
| TNM stage              |     |      |          |
| I                      | 17 (57%) | 13 (43%) | 30 | 0.933 |
| II + III               | 15 (56%) | 12 (44%) | 27 |       |

Correlation of USP22 protein expression with clinicopathology in 57 CCA in 2nd Hospital of Dalian Medical University, China. χ²-value was calculated using the Pearson χ² test, and p < 0.05 was considered a statistically significant difference.
acetylated TAK1 or Akt in SIRT1-silenced RBE (Fig. 4G), suggesting that TAK1 and Akt acetylation depends on SIRT1 in RBE (Supplementary Fig. 4). The same outcomes occurred in USP22-silenced in RBE. Moreover, USP22 overexpression in HCCC cells downregulated acetylation of TAK1 and Akt (Supplementary Fig. 4).

Collectively, we show that USP22 and SIRT1 are part of a protein complex and USP22 regulates SIRT1 deubiquitination. Both USP22
and SIRT1 epigenetically modifies TAK1 and Akt, involving deacetylation a previous unidentified observation in CCA growth.

**Functional association of USP22 with SIRT1 in vitro and in vivo**

To determine the functional interplays between USP22 and SIRT1, we overexpressed SIRT1 in USP22-silenced RBE or QBC939 (namely RBE-shUSP22 + SIRT1 or QBC939-shUSP22 + SIRT1 and the controls of RBE-shUSP22 + EV or QBC939-shUSP22 + EV). SIRT1 overexpression restored capabilities of USP22-silenced RBE and QBC939 cell proliferation, migration and invasion (p < 0.05) (Figs. 5A–D), in conjunction with increased anti-apoptosis in vitro (p < 0.05) (Fig. 5B). SIRT1 overexpression also rescued their cell mobility by triggering them to migrate and invade to the extent that was comparable to the abilities of the controls in vitro (Fig. 5C and D).

We showed that SIRT1 overexpression in USP22-silenced RBE and QBC939 phosphorylated ERK1/2 and Akt (Fig. 5E), and decreased pro-apoptotic Bax, with spontaneously increased anti-apoptotic Bcl-2 expression as analysed by immunoblotting (Fig. 5F). SIRT1 overexpression rewrote an EMT programme by upregulating vimentin and downregulating E-cadherin in USP22-silenced RBE and QBC939. In keeping with these immunoblotting analyses, similar results were observed in USP22-silenced RBE and QBC939 from FACS analysis (Supplementary Fig. 5A–F). Thus, our study suggests that SIRT1 regulates CCA survival and EMT induction, but independently USP22.

We validated these in vitro findings in vivo by subcutaneously injecting SIRT1-silenced USP22-overexpressing HCCC (namely HCCC-USP22 + shSIRT1) and HCCC-USP22 control, or SIRT1 overexpression in USP22-silenced RBE (namely RBE-shUSP22 + SIRT1) and RBE-USP22 control. SIRT1 knockdown inhibited USP22-induced HCCC tumour growth (Fig. 6A), and the sizes and weights of these tumours were almost half of the HCCC-USP22 (p < 0.05) (Fig. 6B and C). Overexpression of SIRT1 stimulated RBE-shUSP22 tumour xenograft growth—the sizes and the weights of the RBE-shUSP22 + SIRT1 tumours were twofold greater than the RBE-shUSP22 control (p < 0.05) (Fig. 6D, E and F).

By injecting these cell lines into mouse tail veins, we detected that decreased the total number of metastatic foci in the mouse lungs of SIRT1-silenced HCCC-USP22, which were half of the HCCC-USP22 control (p < 0.05) (Fig. 6G). Conversely, overexpression of SIRT1 in USP22-silenced RBE generated twofold greater of the metastatic foci than that of the RBE-shUSP22 control mouse lungs (p < 0.05) (Fig. 6H).

Essentially, our clinical analysis of H-score for USP22 and SIRT1 in 57 CCA tissue samples demonstrated a positive correlation between them (p < 0.05) (Supplementary Table 1). We analysed their relationship at mRNA levels in a TCGA dataset and found that they were not significantly correlated (Supplementary Fig. 6), suggesting their post-translational cooperation for CCA.

**DISCUSSION**

Much evidence has shown USP22 is overexpressed in a variety of tumours but if it is protumourigenic posing a contradictory...
outcomes and investigation of its role in CCA remains completely unknown. In the present study, we showed that both high USP22 gene and protein was significantly correlated with the worse prognosis of iCCA, particularly those with highly invasive lesions. USP22 favoured tumour cell proliferation, migration and invasion in vitro and in vivo. The underpinning protumourigenic USP22 on tumour cells was EMT induction, exhibiting loss of epithelial E-cadherin and gain of mesenchymal vimentin, with upregulation of MMP2/9 invasive markers in CCA cell lines. The USP22 deubiquitination-associated SIRT1 stabilization led to the increased downstream ERK/Akt phosphorylation and anti-apoptotic Bcl expression and spontaneously decreased proapoptotic Bax expression. SIRT1 overexpression was capable of functionally restoring the genetically knockdown of the USP22 gene in CCA in vitro and in vivo. Furthermore, the knockdown of SIRT1 led to TAK1 and Akt acetylation, linking the role of SIRT1 plays in regulating deacetylation—a previous unreported mechanism in CCA.

USP22 overexpression is correlated with poor clinical outcomes in carcinomas of salivary duct, esophageal squamous cell and liver [32–34]. That is clearly confirmed here and extended by showing that USP22 was an independent poor prognostic predictor for iCCA. Our analysis in a TCGA dataset indicates that there was no significant correlation of the levels of the USP22 mRNA with the mutation of USP22 in the states of either a shallow deletion, diploid or gain/amplification, suggesting posttranslational regulation of CCA by USP22.

Our determination of USP22 in human CCA cell lines in vitro and in vivo showed that USP22 overexpression was tumorigenic, promoting cell growth, mobility and metastasis, and inducing EMT. Conversely, the shRNA knockdown convincingly reserved the USP22 these protumourigenic functions. These results are in lines with several previous reports [35] suggesting that USP22 is a potential oncogenic driver in regulating the development of CCA. USP22 has been involved in a plethora of physiological and pathophysiological activities, as cell cycle regulation, anti-apoptosis and cancer development [36]. As a component of the deubiquitinating module of the SAGA complex, USP22 deubiquitinates H2B via monouquibination to regulate transcriptional activity and stabilizes SIRT1 for maintaining physiological

---

**Fig. 4** USP22 stabilizes SIRT1 and regulates phosphorylation of Akt and ERK1/2. A HCCC-USP22, HCCC-shControl, RBE-shUSP22 or RBE-shControl cells were prepared for western blot analysis with antibodies to SIRT1, phospho-ERK1/2, ERK1/2, phospho-Akt (Tyr 473), Akt and GAPDH. B RBE-shUSP22/RBE-shControl or QBC939-shUSP22/QBC939-shControl were cultured ± MG132 (10 μM) for 6 h. Cells were lysed and prepared for immunoblotting analysis with antibodies to SIRT1, USP22 and GAPDH. C RBE-shUSP22/RBE-shControl or QBC939-shUSP22/QBC939-shControl were cultured ± cycloheximide (CHX) 50 μg/ml and harvested at the time points of 2 and 6 h, and cells were lysed for immunoblotting analysis with antibodies to SIRT1 and USP22. D Cell lysates from RBE-shControl and RBE-shUSP22 were prepared for reciprocal pull-down and immunoblotting analysis with antibodies to IgG, USP22 and SIRT1. E 293 T cells were grown and cotransfected with Flag-tagged USP22 and Myc-SIRT1, and the cell lysates were prepared for immunoprecipitation and immunoblotting analysis with antibodies to IgG, Flag and Myc. F, G RBE-shControl and RBE-shUSP22 cells were cultured and cell lysates were prepared for immunoprecipitation with antibodies to IgG, SIRT1, TAK1 or Akt. They were analysed by immunoblotting with antibodies to ubiquitin, SIRT1, USP22, pan-acetylation, TAK1, Akt, and GAPDH. All data shown are representative of three independent experiments.
metabolic homeostasis [28]. We extended that further by showing that USP22 deubiquitination was associated with SIRT1 stabilisation, subsequently transducing Akt and ERK tumour survival signal. A similar process in tumour progression also occurs in many other types of tumours, plausibly involving suppression of p53 transcription to prevent cell death and interact with c-Myc oncogene to maintain CCA progression [9, 12, 36–38].

The question remains however if SIRT1 is a CCA promoter or a suppressor when USP22 is deficient. Our present study showed that ectopic expression of SIRT1 greatly enhanced CCA cell growth in vitro and in vivo. The opposite was true when the USP22 gene was knocked down in two different CCA cell lines, RBE and QBC939. It activated tumour survival signalling and restored the induction of EMT, accompanied by decreased pro-apoptotic

Fig. 5 SIRT1 restores CCA growth and metastasis independently of USP22 in vitro. A–D Cell lines of RBE-shUSP22, RBE-shControl, RBE-shUSP22+EV and RBE-shUSP22 + SIRT1 or QBC939-shUSP22, QBC939-shControl, QBC939-shUSP22 + SIRT1 and QBC939-shUSP22+EV were grown for the assay of cell proliferation by CCK-8 (A). They were also prepared for assays of apoptosis by FACS (B), and transwell migration/invasion as shown in Fig. 2 (C–D). All data shown are presented as the mean ± SD (*p < 0.05, n = 3). E–F Cell lines mentioned above were also cultured and the lysates were prepared for immunoblotting analysis with antibodies to SIRT1, USP22, p-Akt and p-ERK1/2, Bax, Bcl-2, E-cadherin, vimentin and GAPDH. All data shown are representative of three independent experiments.
Bax and increased anti-apoptotic Bcl2. This is consistent with the protumourigenic role of SIRT1 in inducing EMT in pancreatic cancer, hepatocellular carcinoma and gastric cancer, but discordant with its EMT inhibition in breast cancer, lung cancer and ovarian cancer [39–44]. Apparently, dual functions of SIRT1 play either protumourigenesis or antitumourignesis, depending on the cellular context of tumour types [45]. SIRT1 may act as a promoter in the context of USP22 for CCA growth.

Furthermore, our present study demonstrates that protumourigenic SIRT1 expression stabilised TAK1 and Akt oncoproteins through deacetylation mediated epigenetic modulation in CCA. TAK1 is a member of the mitogen-activated protein kinase kinase (MAP3K) family that is activated by TGF-β [46]. TAK1 activation promotes cell survival, differentiation, apoptosis, and inflammatory responses [47]. However, TAK1 deacetylation by SIRT1, particularly in the context of tumours, has not been reported previously. Our present study demonstrated that SIRT1 suppression by shRNA increased both TAK1 and Akt acetylation in CCA. Hence the presence of SIRT1 would deacetylate both TAK1 and Akt, and sustain the oncogenic signal cues for CCA development [48–50]. But the exact role of the SIRT1–TAK1–Akt axis in association with epigenetic modification requires a thorough investigation in CCA.

In summary, little is known about the role of USP22 and its relationship with SIRT1 in CCA development. Our present study demonstrates that USP22 is highly expressed in the aggressive iCCA. USP22 stimulates cell proliferation, migration and invasion through EMT induction, by which it deubiquitates and stabilises SIRT1 for CCA development. In conjunction with TAK1 and Akt deacetylation, SIRT1 aggravates CCA interacting with USP22 to epigenetically modulate CCA and facilitate the malignant growth. Thus, their cooperation may pose the synthetic lethality in CCA.

**CODE AVAILABILITY**

Code for TCGA data analysis is available from Dr. Yu Tian (dyqnzy@126.com).

**REFERENCES**

1. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol. 2006;45:856–67.
2. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261–80.
3. Khan SA, Taylor-Robinson SD, Toledano MB, Andersson JB, Invernizzi P, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261–80.
4. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806–13.
5. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem. 2012;81:203–29.
6. Ciechanover A, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806–13.
7. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002;82:373–428.
8. Reyes-Turcu FE, Venti H, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem. 2009;78:363–97.

9. Lin Z, Yang H, Kong Q, Li J, Lee SM, Gao B, et al. USP22 antagonizes S35 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell. 2012;48:484–94.

10. Lang G, Bonnet J, Umlauf D, Karmodiya K, Koffler J, Sterle M, et al. The tightly controlled and deubiquitination activity of the human SAGA complex differentially modifies distinct gene regulatory elements. Mol Cell Biol. 2011;31:7334–44.

11. Zhao Y, Lang G, Ito S, Bonnet J, Metzger E, Sawatsubashi S, et al. A TFCIT/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell. 2008;29:92–101.

12. Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, et al. The putative cancer stem cell stem marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 2008;29:102–11.

13. Kim D, Hong A, Park HI, Shin WH, Yoo L, Jeon SJ, et al. Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells. J Cell Physiol. 2017;232:3664–76.

14. Ning Z, Wang A, Liang J, Xie Y, Liu J, Yan Q, et al. USP22 promotes epithelial-mesenchymal transition via the FAK pathway in pancreatic cancer cells. Oncol Rep. 2014;32:1451–8.

15. Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P, et al. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell. 2013;14:543–56.

16. Xu G, Cai J, Wang L, Jiang L, Huang J, Hu R, et al. MicroRNA-30e-5p suppresses non-small cell lung cancer tumorigenesis by regulating USP22-mediated Sirt1/AKT/MPR1 signaling. Exp Cell Res. 2018;362:268–78.

17. Wang A, Ning Z, Lu C, Gao W, Liang J, Yan Q, et al. USP22 induces cisplatin resistance in lung adenocarcinoma by regulating gammaH2AX-mediated DNA damage repair and Ku70/Bax-mediated apoptosis. Front Pharm. 2017;8:274.

18. Ling S, Li J, Shan Q, Dai H, Lu D, Wen X, et al. USP22 mediates the multidrug resistance of hematopoietic carcinoma via the SIRT1/AKT/MPR1 signaling pathway. Mol Oncol. 2017;11:682–95.

19. Chipumuro E, Henriksson MA. The ubiquitin hydrolase USP22 contributes to 3′ end processing of JAK/STAT3-induced genes. FASEB J. 2012;26:842–53.

20. Wang S, Zhang X, Wang C, Luo H, Lin S, Sun H, et al. USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer. Cell Death Differ. 2020;27:1331–45.

21. Kosinski RL, Helms M, Zerche M, Wohin L, Dysa A, Prokakis E, et al. USP22-dependent HPS90A081 expression promotes resistance to HSPO9 inhibition in mammary and colorectal cancer. Cell Death Dis. 2019;10:1–11.

22. Liu Y, Yang Y, Xu H, Dong X. Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinoma. Diagn Mol Pathol. 2010;19:194–200.

23. Zhou A, Lin K, Zhang S, Chen Y, Zhang N, Xue J, et al. Nuclear GSK3beta promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitlylation by USP22. Nat Cell Biol. 2016;18:954–66.

24. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and cancer. Nat Rev Endocrinol. 2012;8:22–31.

25. Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, Stanek TJ, et al. The tightly controlled and deubiquitination activity of the human SAGA complex differentially modifies distinct gene regulatory elements. Mol Cell Biol. 2011;31:7334–44.

26. Young MJ, Hsu KC, Lin TE, Chang WC, Hung JJ. The role of ubiquitin-specific peptidases in cancer progression. J Biomed Sci. 2019;26:126.

27. Zhang Y, Liao ZW, Yu HW, Song XJ, Liu Y, Shi XY, et al. USP22-mediated silencing of the ubiquitin-specific protease 22 gene restricted cell proliferation and affected the Akt pathway in nasopharyngeal carcinoma. Cancer Biol Ther. 2015;16:888–96.

28. Tang B, Yang Z, Gao W, Ling J, Wang AM, Luo HF, et al. Ubiquitin-specific protease 22induced autophagy is correlated with poor prognosis of pancreatic cancer. Oncol Rep. 2014;32:2726–34.

29. Wauters E, Sanchez-Arevalo Lobo VJ, Pinho AV, Massow A, Herranz D, Wu J, et al. Sirtuin-1 regulates acinar-to-duodenal metaplasia and supports cancer cell viability in pancreatic cancer. Cancer Res. 2013;73:2357–67.

30. Chen J, Zhang B, Wong N, Lo AW, To KF, Chan AW, et al. Sirtuin-1 regulates acinar-to-duodenal metaplasia and supports cancer cell viability in pancreatic cancer. Cancer Res. 2013;73:1175–86.

31. Sun L, Li H, Chen J, Dhemnaut V, Zhao Y, Yang Y, et al. A SUMOylation-dependent pathway regulates SIRT1 transcription and lung cancer metastasis. J Natl Cancer Inst. 2013;105:867–80.

32. Sun L, Li H, Chen J, Iwasaki Y, Kubota T, Matsuoka M, et al. PIASy mediates hypoxya-induced SIRT1 transcriptional repression and epithelial-to-mesenchymal transition in ovarian cancer cells. J Cell Sci. 2013;126:3939–47.

33. Palmirotta R, Cives M, Della-Morte D, Capuani B, Lauro D, Guadagni F, et al. Sirtuins and cancer: role in the epithelial-mesenchymal transition. Oxid Med Cell Longev. 2016;2016:3031459.

34. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi U, Ueno N, et al. Identification of a member of the MAPKPPX family as a potential mediator of TGF-beta signal transduction. Science. 1995;270:2008–11.

35. Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci. 2012;33:522–30.

36. Ghosh S, Hayden MS. Celebrating 25 years of NF-kappaB research. Immune Rev. 2012;246:5–11.

37. Paquette N, Conlon J, Sweet C, Rus F, Wilson L, Pereira A, et al. Serine/threonine acetylation of TGFbeta-activated kinase (TAK1) by Yersinia pestis YopI inhibits innate immune signaling. Proc Natl Acad Sci USA. 2012;109:12710–15.

38. Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, Parekh V, et al. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PKD1 during tumorigenesis and cardiac hypertrophy. Sci Signal. 2011;4:ra46.

ACKNOWLEDGEMENTS

We would like to thank Professor Alison Banham, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, for making valuable comments on this manuscript.

AUTHOR CONTRIBUTIONS

LMW, BT and MLY conceived and designed the experiments. LMW, ZMG and RL prepared the patient samples. YT, BT, CYW, YW, JKM and YFY performed the experiments. YT, BT and SC analysed the data. SC and YT wrote the article. All authors read and approved the manuscript.

FUNDING

This work was partially supported by the National Natural Science Foundation of China (81272368, 81471755, 81360367, 81560393), the Clinical Capability Construction Project for Liaoning Provincial Hospitals (LNCCC-803-2014), the Natural Science Foundation of Guangxi (2015JJA031, 2016XNSFA380003), Guangxi Science Fund for Distinguished Young Scholars Program (2016GXXSF038003) and United Found of the Second Hospital of Dalian Medical University and Dalian Institute of Chemical Physics, Chinese Academy of Sciences (U15022003), SC was partially funded by Alan Morement Memorial Foundation, UK (2018/116).

ETHICS

All procedures with mice were conducted in accordance with the guidelines of the Dalian Medical University Animal Care and Use Committee.
COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-03940-0.

Correspondence and requests for materials should be addressed to B.T., S.C. or L.W.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.